Summary
A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and antiviral activity of orally administered study drug regimens in hospitalized or non-hospitalized infants and children aged 28 days to 24 months infected with RSV (respiratory syncytial virus).
Register to download
Collaboration Advances Small Pharma Company’s Pediatric Development Plan to First-in-Pediatrics RSV Study
You may also be interested in:
Page
Therapeutic Expertise
A core aspect of the drug development landscape has been and always will be an intimate expertise in therapeutic areas. Our experts will partner with…
Blog
Ask the Experts: What Dangers Does the COVID-19 Pandemic Bring to Respiratory Disease Patients?
Over the last eight months, the world has become familiar with how COVID-19 affects the human body and spreads. COVID-19 is a respiratory disease…
Blog
Ask the Experts: What is the Current Clinical Development for Respiratory Conditions?
COVID-19 is a disease that heavily affects the respiratory systems of those that contract the disease. Inspired by Respiratory Care Week, we must pay…